PICTURE试验:经会阴靶向前列腺穿刺活检的准确性—视觉估计与图像融合对比
PICTURE前瞻性试验纳入249例需重复前列腺活检的患者,评估多参数磁共振靶向活检对临床显著前列腺癌的检出,并比较视觉估计与图像融合靶向。结果显示靶向活检能准确检出临床显著癌并减少 insignificant 癌过度诊断,但需联合视觉估计与图像融合以最大化检出。
要点
- 磁共振靶向活检可准确检出临床显著前列腺癌并减少 insignificant 癌过度诊断。
- 视觉估计与图像融合靶向检出率相似,但各自遗漏对方检出的部分显著癌。
- 为最大化检出,应同时采用视觉估计与图像融合靶向活检。
核心结论
- 磁共振靶向活检能准确检出临床显著前列腺癌并减少 insignificant 癌的过度诊断。
- 为最大化检出,需同时采用视觉估计与图像融合靶向活检。
研究设计与样本
- PICTURE为前瞻性、伦理委员会批准试验(NCT01492270),2012年1月11日至2014年1月29日连续纳入249例患者。
- 所有患者行多参数磁共振后盲法行经会阴模板前列腺映射活检;200例有病灶者先行视觉估计与图像融合靶向活检。
- 主要终点临床显著前列腺癌定义为Gleason 4+3或以上和/或任一级别癌长度≥6 mm。
主要发现
- 经会阴模板前列腺映射活检检出97例(48.5%)临床显著前列腺癌和85例(42.5%)insignificant 癌。
- 多参数磁共振靶向活检检出81例(40.5%)临床显著前列腺癌和63例(31.5%)insignificant 癌。
- 18例(9%)靶向活检为临床显著癌而模板映射活检为良性或临床不显著。
- 34例(17%)模板映射活检检出临床显著癌而靶向活检未检出,约半数位于非靶向区域。
- 169例中视觉估计与图像融合分别检出53例(31.3%)和48例(28.4%)临床显著癌(McNemar检验p=0.5322)。
关键数值与推荐
- 临床显著前列腺癌定义:Gleason 4+3或以上和/或任一级别癌长度≥6 mm。
- 视觉估计与图像融合靶向检出临床显著癌的差异无统计学意义(McNemar检验p=0.5322)。
临床怎么用
- 对需重复前列腺活检的患者,磁共振靶向活检可用于准确检出临床显著前列腺癌并减少 insignificant 癌过度诊断。
- 临床操作中应同时采用视觉估计与图像融合靶向活检以最大化临床显著癌检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the detection of clinically significant prostate cancer using magnetic resonance imaging targeted biopsies and compared visual estimation to image fusion targeting in patients requiring repeat prostate biopsies. MATERIALS AND METHODS: The prospective, ethics committee approved PICTURE trial (ClinicalTrials.gov NCT01492270) enrolled 249 consecutive patients from January 11, 2012 to January 29, 2014. Men underwent multiparametric magnetic resonance imaging and were blinded to the results. All underwent transperineal template prostate mapping biopsies. In 200 men with a lesion this was preceded by visual estimation and image fusion targeted biopsies. As the primary study end point clinically significant prostate cancer was defined as Gleason 4 + 3 or greater and/or any grade of cancer with a length of 6 mm or greater. Other definitions of clinically significant prostate cancer were also evaluated. RESULTS: Mean ± SD patient age was 62.6 ± 7 years, median prostate specific antigen was 7.17 ng/ml (IQR 5.25-10.09), mean primary lesion size was 0.37 ± 1.52 cc with a mean of 4.3 ± 2.3 targeted cores per lesion on visual estimation and image fusion combined, and a mean of 48.7 ± 12.3 transperineal template prostate mapping biopsy cores. Transperineal template prostate mapping biopsies detected 97 clinically significant prostate cancers (48.5%) and 85 insignificant cancers (42.5%). Overall multiparametric magnetic resonance imaging targeted biopsies detected 81 clinically significant prostate cancers (40.5%) and 63 insignificant cancers (31.5%). In the 18 cases (9%) of clinically significant prostate cancer on magnetic resonance imaging targeted biopsies were benign or clinically insignificant on transperineal template prostate mapping biopsy. Clinically significant prostate cancer was detected in 34 cases (17%) on transperineal template prostate mapping biopsy but not on magnetic resonance imaging targeted biopsies and approximately half was present in nontargeted areas. Clinically significant prostate cancer was found on visual estimation and image fusion in 53 (31.3%) and 48 (28.4%) of the 169 patients (McNemar test p = 0.5322). Visual estimation missed 23 clinically significant prostate cancers (13.6%) detected by image fusion. Image fusion missed 18 clinically significant prostate cancers (10.8%) detected by visual estimation. CONCLUSIONS: Magnetic resonance imaging targeted biopsies are accurate for detecting clinically significant prostate cancer and reducing the over diagnosis of insignificant cancers. To maximize detection visual estimation as well as image fusion targeted biopsies are required.
引用
- Simmons LAM, Kanthabalan A, Arya M, et al. Accuracy of Transperineal Targeted Prostate Biopsies, Visual Estimation and Image Fusion in Men Needing Repeat Biopsy in the PICTURE Trial. J Urol. 2018. PMID: 30017964. doi:10.1016/j.juro.2018.07.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。